Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

B SHANGHAI, March 31, 2026 /PRNewswire/ — 31 March 2026, Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter, HKEX code: 02256) announced that its independently developed, highly selective,…

posteditor
posteditor
Articles: 27298

Other News